Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 19, 2026.

Intrinsic Disorder and Posttranslational Modifications: The Darker Side of the Biological Dark Matter

April L. Darling, Vladimir N. Uversky

Frontiers in Genetics · 2018 · Review

doi:10.3389/fgene.2018.00158

Abstract

Intrinsically disordered proteins (IDPs) and intrinsically disordered protein regions (IDPRs) are functional proteins and domains that devoid stable secondary and/or tertiary structure. IDPs/IDPRs are abundantly present in various proteomes, where they are involved in regulation, signaling, and control, thereby serving as crucial regulators of various cellular processes. Various mechanisms are utilized to tightly regulate and modulate biological functions, structural properties, cellular levels, and localization of these important controllers. Among these regulatory mechanisms are precisely controlled degradation and different posttranslational modifications (PTMs). Many normal cellular processes are associated with the presence of the right amounts of precisely activated IDPs at right places and in right time. However, wrecked regulation of IDPs/IDPRs might be associated with various human maladies, ranging from cancer and neurodegeneration to cardiovascular disease and diabetes. Pathogenic transformations of IDPs/IDPRs are often triggered by altered PTMs. This review considers some of the aspects of IDPs/IDPRs and their normal and aberrant regulation by PTMs.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Protein posttranslational modifications (PTMs) represent an important means for the natural increase in the proteome complexity and serves as one of the factors (in addition to the allelic variations and alternative splicing, together with some other pre-translational mechanisms, e.g., mRNA editing, allowing production of numerous mRNA variants), defining the ability of one gene to efficiently encode a set of distinct protein molecules, known as proteoforms. Since in eukaryotic organisms, the number of functionally different proteins dramatically exceeds the number of protein-encoding genes, one can reasonably argue that the complexity of a biological system is mostly determined by its proteome size and not by the size of genome. Although the number of human protein-coding genes is approaching 20,700, the actual human proteome includes a few hundred thousand, if not millions, of functionally different proteins. Because PTMs can affect protein activity, folding, interactions, localization, stability, and turnover, they play an important role in defining the protein structure-function continuum, according to which a protein has multiple structurally and functionally different states, proteoforms, generated by various mechanisms (including PTMs). It was also pointed out that combination of alternative splicing, PTMs, and intrinsic disorder represents an important means for promotion of the alternative, context-dependent states of gene regulatory networks, thereby serving as a critical tool for controlling of a broad range of cellular responses, including cell fate specification.

Intrinsic disorder and protein conformational dynamics represent another means used by nature to generate proteoforms. In fact, it was pointed out that even without alternative splicing, PTMs, or mutations, any protein, being a dynamic conformational ensemble, represents a set of basic (or intrinsic, or conformational) proteoforms; i.e., molecules with identical amino acid sequences but with different structures and, potentially, with different functions. Obviously, any mutated, modified, or alternatively spliced form of a protein [i.e., any member of the inducible (or modified) proteoforms] also exists as a structural ensemble and thereby represents a set of conformational proteoforms. Protein functions and structural ensembles of basic and induced proteoforms can be significantly altered by placing proteins in crowded cellular environment. This environment originates from high concentrations of various biological macromolecules inside the cells that limit available volume and restrict amounts of free water. Finally, functionality per se can be considered as a factor generating functioning proteoforms. In other words, because of all these factors, any given protein exists as a set of basic, induced and functioning proteoforms. As a result, the actual relationships between a gene and a protein function follow the ‘one-gene – many-proteins – many-functions’ concept. This is in a striking contrast to the classical ‘one-gene – one-protein’ view, where each gene produces a single enzyme for controlling a single step of a metabolic pathway.

Posttranslational modifications are included into the ‘dark matter of biology’ concept that is attributed to “important, yet invisible species of molecules and proteins that interact weakly but couple together to have huge and important effects in many biological processes… [and that] remains mostly hidden, because our tools were developed to investigate strongly interacting species and folded proteins”. Curiously, many PTMs are intimately linked to another component of the ‘dark matter of biology,’ namely intrinsically disordered proteins (IDPs) and IDP regions (IDPRs), making such disorder-centered PTMs the darker side of the biological dark matter. This review is dedicated to the analysis of an intriguing connection between intrinsic disorder and PTMs, thereby representing an attempt to shed some light to the darker corner of the dark matter of biology.

Intrinsically Disordered Proteins, Their Abundance and Biological Functions

The protein functionality is not always associated with the presence of unique 3D structure in a protein molecule. Instead, functional states of many proteins constitute dynamic conformational ensembles of interconverting structures, where a whole protein or its noticeable regions lack stable tertiary and/or secondary structure. These floppy but biologically active proteins and regions are currently known as IDPs and IDPRs. In relation to the subject of this special issue, IDPRs frequently contain sites of proteolytic attack and include various PTM sites.

Figure 1 shows that IDPs and IDPRs are abundantly present in all proteomes analyzed to date, with the proteome disorder levels typically increasing with the increase of the organism complexity. Furthermore, many IDPs/IDPRs are evolutionary conserved, indicating that at least some protein functionality is determined by intrinsic disorder. In fact, order and disorder are both needed for protein functionality, and functional repertoire ascribed to IDPs/IDPRs complement catalytic and transport functions of ordered proteins and domains. Therefore, the unbiased consideration of protein functionality should include both ordered proteins/domains and IDPs/IDPRs. This idea is illustrated by Figure 2 showing that protein structure-function interrelationship includes two pathways, where the ‘sequence-to-structure-to-function’ paradigm can be utilized for the description of functionality of transport proteins and enzymes, whereas the ‘sequence-to-dynamic conformational ensemble-to-function’ paradigm represents a key for understanding the functions of IDPs/IDPRs preferentially involved in control, recognition, regulation, and signaling. Furthermore, the ‘protein trinity’ or the ‘protein quartet’ models were used for the conceptualization of protein functionality. In these models, function of a protein can be associated with ordered, molten globule-like (collapsed-disordered), pre-molten globule-like (partially collapsed-disordered) or coil-like (extended-disordered) conformations and/or from the transitions between all these conformations.

Some illustrative biological activities of IDPs/IDPRs include protein and RNA chaperone action, control of transcription and translation, storage of small molecules, location of PTM sites, regulation of the cell cycle and division, control of development, regulation and modulation of the self-assembly of large multi-protein complexes, and moderation of signal transduction, to name a few. The existence of at least 28 separate disorder-based functions was proposed based on the careful analysis of literature on >150 completely disordered proteins or proteins containing functional IDPRs. Globally, functional IDPs/IDPRs have very different modes of action serving as entropic chains, display sites, assemblers, effectors, chaperones, and scavengers.

Because of their flexible nature, IDPs/IDPRs have some remarkable functional advantages over their ordered counterparts, including their ability to be promiscuous binders engaged in efficient interactions with different and often unrelated targets. One of the said functional advantages of IDPs/IDPRs is their ability to (partially) fold (or undergo disorder-to-order transitions) upon interaction with specific partners. In relation to the reversible signaling interactions, such binding-induced disorder-to-order transitions allow IDPs/IDPRs to participate in highly specific but weak interactions. Furthermore, IDPs/IDPRs can fold on a template-dependent manner. This provides them with an ability to attain very different structures at interaction with different binding partners.

Although promiscuous interactivity and ability to fold at binding to specific partners represent a characteristic signature of disorder-based functionality, one should remember that IDPs/IDPRs have numerous ‘entropic chain activities.’ These activities rely on the flexibility, plasticity, and pliability of the protein backbone and therefore that do not require coupled binding and folding. The voltage gated ion channel can serve as an illustrative example of such entropic chain activities. Activity of this channel involves cyclic transitions between closed (sensitive to voltage), open, and inactive (insensitive to voltage) states. In structure of such channels, a highly flexible ‘chain’ connects a small folded domain, ‘ball,’ to the channel opening. Channels utilize an entropic clock mechanism for inactivation, where the random motions of the ‘ball-and-chain’ unit provide a means for the ‘ball’ to eventually plug into the open channel and inactivate it. It was pointed out that timing of such channels relies on flexibility and length of their disordered ‘chains.’ In fact, since the time of closure of such channels is inversely proportional to the square of the length of their ‘chains’, inactivation is faster when the ‘chain’ is shorter.

Entropic bristle domain (EBD); i.e., the time-averaged three-dimensional area swept out by the thermally driven motion of a disordered polypeptide, represents another example of entropic activity. Obviously, EBD that occupies a defined area but does not have a fixed structure is different from a traditional protein domain, which is a conserved part of a protein structure that can evolve, function, and exist independently of the rest of the polypeptide chain. Illustrative carriers of functional EBDs are given by the neurofilament proteins found in the major cytoskeletal components of the axonal cell, neurofilaments, that among other functions, are needed to maintain the bore of the axon. The needed spacing between the neurofilaments is kept by the action of the entropic brush formed by EBDs that project from the NF-M and NF-H neurofilament proteins.

Overall, multiple functional advantages were ascribed to IDPs/IDPRs to explain their prevalence in various proteomes and their broad use in various biological processes. Natural abundance of IDPs/IDPRs is clearly related to their multifunctionality, which, in its turn, is linked to their specific structural features. Sections below consider peculiarities of structural organization and conformational behavior of IDPs/IDPRs to better understand the uniqueness of these intriguing members of protein universe.

Some Basic Structural Properties of IDPs/IDPRs

Structural description of IDPs/IDPRs relies on the dynamic conformational ensemble representation, where the members of such conformational ensembles interconvert on a number of timescales. By analogy with the conformational states of typical globular proteins that, depending on the environmental conditions, may exist in at least four different conformations: folded (ordered), molten globule, pre-molten globule, and coil-like, IDPs, being considered at the whole protein level, can be classified as native molten globules containing collapsed form of disorder, native pre-molten globules possessing semi-collapsed form disorder, and native coils with extended form of. This is illustrated by Figure 3 schematically representing these three types of disorder at the whole protein level.

One should keep in mind, however, this classification represents a clear oversimplification, since order and disorder are not homogeneously distributed within a protein molecule. In fact, analysis of crystal structures of various proteins deposited in PDB revealed that they are not only characterized by the presence of regions with high B-factor that reflects the high uncertainty in atom positions in the model, but systematically contain long regions of missing electron density that often correspond to IDPRs [in fact, only about 7% of PDB entries devoid intrinsic disorder], and also contain ambiguous regions, where different structures of the same protein disagree in terms of the presence or absence of missing residues. It is likely that similar levels of disorderedness (collapsed, semi-collapsed, and extended forms of disorder) discussed for the whole proteins can also be found in protein regions, indicating that both IDPs and IDPRs can be differently disordered. These observations suggest that proteins, in general, are characterized by non-homogeneous distribution of foldability and, as a consequence, by a high spatiotemporal heterogeneity, where different parts of a protein molecule are ordered (or disordered) to a different degree. In other words, globally, structural space of functional proteins represents a continuous spectrum of conformations with different degree and depth of disorder. This structural spectrum spreads from fully ordered to completely disordered proteins and includes a myriad of differently (dis)ordered species between these two extremes. Therefore, protein structural space represents a structure-disorder continuum with no clear boundary between ordered proteins and IDPs. It was also pointed out that because of the presence of different levels and depths of intrinsic disorder, proteins are characterized by the mosaic structure and typically contain foldons (i.e., independently foldable regions), inducible foldons (disordered regions that can fold at interaction with binding partner), semi-foldons (IDPRs that are always in the semi-folded state), non-foldons (IDPRs with entropic chain activities), and unfoldons (or conditionally disordered protein regions, which, in order to become functional or to make a protein active, have to undergo order-to-disorder transition).

Peculiarities of Conformational Behavior of IDPs/IDPRs

The free energy landscape of an extended IDP/IDPR is dramatically different from that of ordered globular protein or domain. In fact, if the energy landscape of an ordered protein has a funnel-like shape with a well-defined global energy minimum corresponding to unique protein structure, the free energy landscape of an IDP can be described as a ‘hilly plateau,’ with hills on the plateau corresponding to the forbidden conformations and with numerous local energy minima. Such free energy landscape reflects the existence of numerous conformations that constitutes the dynamic conformational ensemble of an IDP. It also shows that such a protein that does not have stable conformation, possessing instead a highly frustrated nature. The shape of such energy landscape can be easily changed even by minimal changes in the local environment of an IDP. This contrasts high conformational stability of ordered proteins originated from their relatively robust funnel-like energy landscapes. Therefore, the ‘hilly plateau’-like energy landscape determines conformational plasticity of an IDP/IDPR and its ability to fold differently depending on the environmental conditions, where any (even rather subtle) changes in the IDP/IDPR environment might have very strong effects on the protein/region structure leading to the formation of very different structures.

Because of the IDPs/IDPRs are characterized by highly biased amino acid compositions, their conformational behavior is noticeably different from that of ordered proteins and domains. In fact, proteins with extended disorder (which are typically depleted in hydrophobic residues, but enriched in charged and polar residues) were shown to partially fold at increase in temperature, which is in striking opposition to globular proteins and domains that typically unfold at heating. This structure-forming effect of elevated temperature was attributed to the temperature-driven increase in the strength of the hydrophobic interactions that leads to a stronger hydrophobic attraction at higher temperatures. Similarly, a decrease (or increase) in pH was shown to induces partial folding of many extendedly disordered proteins characterized by high net charges at neutral pH. This is because at extreme pH, the net charge of such proteins decreases, causing the decrease in their charge-charge intramolecular repulsion. This permits formation of a partially folded conformation due to the hydrophobicity-driven collapse of polypeptide chain.

Intrinsically disordered proteins/IDPRs are characterized by highly dynamic and heterogeneous structures that are extremely sensitive to changes in the environment and that determine unique functional repertoire of disordered proteins. Since PTMs do alter local physical and chemical properties of proteins, changing their charge, flexibility, and hydrophobicity, such modifications serve as crucial regulators of IDP/IDPR functions and structures. Therefore, sections below, in addition to the introduction of the natural PTM variability, provide an outline of the roles that PTMs play in the regulation of IDPs/IDPRs.

Posttranslational Modifications

As it follows from their definitions, PTMs are chemical changes affecting proteins after their biosynthesis, with almost every protein being potentially able to undergo PTMs. Changes induced by PTMs to protein structure are many. Various chemical groups, carbohydrates, lipids, and even entire proteins or nucleic acids can be covalently added to amino acid side chains. Proteins can also undergo enzymatic cleavage of peptide bonds or removal of various chemical groups. Since different PTMs can differently affect physicochemical properties of a protein, different modifications can graft different functions to the same protein. Although natural variability of PTMs is very broad, these modifications are typically very specific. Many PTMs are catalyzed by special enzymes that recognize particular motifs in target sequences of specific proteins. Some PTMs (e.g., phosphorylation, acetylation, glycosylation, lipidation, methylation, and nitration) are readily reversible due to the concert action of modifying and demodifying enzymes. Such and interplay between the conjugating and deconjugating enzymes represents an economical and rapid way of the controlling the protein function. Furthermore, although mutations (which represent another means of changing the chemical properties of a polypeptide chain) can only occur once per position, different forms of PTMs may happen in tandem.

Diversity of PTMs and Their Classifications

Posttranslational modifications represent an important means for the increase in the variability and diversity of protein structures and functions via extension of the range of structures and physico-chemical properties of amino acids. It was pointed out that although there are 20 primary amino acids typically utilized in protein biosynthesis, in reality, because of various PTMs, proteins might contain more than 140 chemically different residues. To this end, large portion of the genomes of higher eukaryotes (as much as 5%) represents genes that encode PTM-related enzymes. Altogether, as many as 300 PTMs are known to occur physiologically in proteins.

Posttranslational modifications are abundantly present in nature. For example, between at least one-fifth and a half of proteins are expected to be glycosylated. The most common PTMs are covalent removal or addition of various groups, formation of disulfide bonds, and specific cleavage of protein precursors. According to the PTM Curator, most often proteins undergo phosphorylation, acetylation, N-linked glycosylation, amidation, hydroxylation, methylation, O-linked glycosylation, ubiquitylation, attachment of pyrrolidone carboxylic acid or gamma-carboxyglutamic acid, sulfation, sumoylation, palmitoylation, C-linked glycosylation, ADP-ribosylation, myristoylation, farnesylation, nitration, formylation, geranyl-geranylation, deamidation, S-nitrosylation, citrullination, S-diacylglycerol cysteine modification, GPI anchoring, bromination, and FAD addition. Diversity of PTMs found in proteins is illustrated by Table 1, which not only shows that due to the various PTMs, side chains of all natural amino acids can be chemically diversified, but also emphasizes that each amino acid residue can be affected by many different PTMs. However, although all amino acid residues can be modified, most commonly PTMs affect side chains that can act as either strong (C, D, E, H, K, M, R, S, T, and Y) or weak (N and Q) nucleophiles.

All sides of protein life in a cell are affected by PTMs, which can regulate protein folding, target proteins to specific subcellular compartments, control interaction of proteins with their partners, modulate catalytic activity, or affect signaling and recognition functions. Functions of many proteins rely on multiple different PTMs, and modified sites in such multi-PTMed proteins are utilized individually for mediation of specific protein activities or used together for controlling molecular interactions and for modulation of the overall protein activity and stability. An illustrative example of such multi-PTMed proteins is given by histones, different stages of action of which require acetylation, ADP-ribosyation, methylation, phosphorylation, SUMOylation and ubiquitylation. The N-terminal tails of core histones protruding from the nucleosome core and needed to mediate chromatin compaction are known to contain an astonishing number of PTM sites. Furthermore, over 30 histone modifications have been also identified in the core domains of these proteins.

Because of their variability, PTMs can be grouped and classified on multiple ways. For example, depending on the stages of the protein life at which they were introduced, PTMs can be ‘early’ or ‘late’ and can give very different outputs. In fact, some proteins are known to be modified shortly after completion of their biosynthesis and before the final steps of their folding. The corresponding ‘early’ PTMs can influence the efficiency of protein folding, or affect protein conformational stability, or direct the nascent protein to distinct cellular compartments thereby defining its cellular fate. The ‘late’ PTMs occur after the completion of protein folding and localization. They can activate, deactivate, or modulate the biological activity of target proteins. PTMs can also be classified based on the new modification-enabled functionality, such as gain of the catalytic function (e.g., resulting from phosphopantetheinylation, biotinylation, or lipoylation), membrane localization (e.g., caused by glypiation, geranylgeranylation, myristoylation, palmitoylation, prenylation, etc.), and proteolytic destruction by proteasomes (via ubiquitylation).

Another classification of PTMs is based on the underlying molecular mechanisms, such as functional group addition (e.g., phosphorylation, acylation, glycosylation, etc.), covalent conjugation of peptides and small proteins to the main polypeptide chain (e.g., ISGylation, neddylation, SUMOylation, ubiquitination, etc.), change in the physico-chemical properties of amino acids (citrullination, deamidation, deimidation, oxidation, etc.), and proteolytic cleavage. PTMs can also be classified based on the description of the fragment of coenzyme or cosubstrate attached to the modified protein and the chemical nature of the protein modification, e.g., ATP-dependent phosphorylation, acetyl CoA dependent acetylation, NAD-dependent ADP ribosylation, CoASH-dependent phosphopantetheinylation, phosphoadenosinephosphosulfate (PAPS)-dependent sulfurylation, and S-adenosylmethionine (SAM)-dependent methylation.

Posttranslational Modifications and Intrinsic Disorder

Already in early IDP-related studies, it has been pointed out that many PTM sites are frequently associated with IDPRs. Therefore, in addition to the aforementioned classifications of PTMs based on the modulation molecular mechanisms or modulation-enabled functions, PTMs can also be grouped according to the conformational requirements of the potential modification sites. This classification generates two major PTM groups, where modifications are associated either with structured regions or with IDPRs. Tables 2, 3 list some of the PTMs associated with IDPs/IDPRs and ordered proteins and domains, respectively. Curiously, PTMs targeting ordered regions, such as covalent attachment of quinones and organic radicals, formylation, oxidation, and protein splicing introduce new chemical moieties needed for novel catalytic functions, or changing of the existing enzymatic activity, or modulation of the protein conformational stability. On the other hand, PTMs preferentially targeting IDPRs, such as phosphorylation, acetylation, and methylation, are typically used for modifications of the regulatory and signaling regions in target proteins that are engaged in specific but weak interactions with their partners. For example, p53- and p14-ARF-binding regions of the Mdm2 contain the majority of the phosphorylation sites of this protein. Similarly, the phosphorylation of PEST motifs of many proteins controls their ubiquitin-mediated degradation. The biological activities of various proteins involved in signal transduction are modulated by phosphorylation. Furthermore, this PTM can alter gene expression by modulating the binding affinity of transcription factors to their coactivators and DNA, and also can affect cell growth and differentiation.

Some PTMs Are Preferentially Found in IDPRs, Why?

Mechanistically, the prevalence of intrinsic disorder in the display sites of proteins targeted for certain PTMs is defined by the fact that structural pliability associated with high conformational dynamics of potential modification sites is crucial for the efficient action of a modifying enzyme on a multitude of different target proteins. In other words, such association between PTMs and IDPRs represents a solution for the apparent conundrum, where the modifying enzymes have to act following the ‘one-lock-many-keys’ scenario instead of the classical ‘lock-and-key’ mode of the enzyme action. The scale of the problem with too many ‘keys’ for a given ‘lock’ is given by kinases and phosphatases utilized in protein phosphorylation-dephosphorylation cycles. Protein kinases and phosphatases are among the largest gene families in eukaryotes [e.g., yeast and mouse genomes encode 119 and 540 kinases, respectively, and there are ∼520 (1019) kinase- and 150 (300) phosphatase-coding genes in human (or Arabidopsis thaliana) kinome]. However, in any given proteome, the number of proteins undergoing reversible phosphorylation is noticeably larger than the number of kinases and phosphatases. In fact, phosphorylation is expected to affect functions of at least one-third of eukaryotic proteins. In humans, more than two-thirds of the 21,000 proteins were shown to be phosphorylated, and it is likely that more than 90% are actually subjected to this type of PTM. Based on the very conservative estimate of the penetrance of phosphorylation in human proteome (66.7%), each human kinase act on 27 target proteins, whereas each human phosphatase can dephosphorylate 93 clients. These numbers increase to 36 and 126 clients for each human kinase and phosphatase, respectively, if one would use the less conservative estimate of the prevalence of phosphorylation in human proteome (90%). However, the reality is even more complex, since many proteins are known to have multiple phosphorylation sites. Similar situation is observed for glycosylation (the covalent addition of carbohydrate moieties to specific amino acids), since almost half of all proteins typically expressed in a cell undergo this modification. Similarly, although the vast majority of human proteins end their lives via proteasomal degradation and although functionality and cellular localization of many proteins are regulated by ubiquitination–deubiquitination sites, the human genome codes for ∼600 E3 ubiquitinating ligases and 80 deubiquitinases.

Therefore, for each ‘lock’-containing enzyme (kinase, phosphatase, or any other modifying enzyme that targets multiple unrelated proteins) there are numerous ‘keys’ (modification sites of protein targets). This observation raises an important question on what allows these modifying enzymes to be engaged in the ‘one-lock-many-keys’ activity. An obvious solution is in relaxing classical ‘lock-and-key’ model by allowing structural flexibility. In fact, the problem is easily solved if instead of a ‘rigid key’ a modifiable protein is using a ‘flexible lock pick.’ In line with these consideration is a well-known fact that substrates are typically bound to the kinase rather weakly, despite the high specificity of the phosphorylation process. Such combination of low affinity and high specificity is a characteristic feature of signaling interactions, which are commonly based on intrinsic disorder. Often, such low affinity – high specificity protein-protein interactions rely on the coupled binding and folding of at least on of the partners. The corresponding disorder-to-order transition is characterized by a positive free energy change that reduces the magnitude of the negative free energy change associated with the interactions and defines the low binding affinity.

Figure 4 further illustrates the mostly disordered nature of regions containing various PTM sites. Crystal structures of complexes between several modifying enzymes, such as kinase, phosphatase, glycosyltransferase, deacetylase, and methyltransferase, and peptides derived from their corresponding target proteins are shown (see Figures 4A–E, respectively). In all these cases, despite the obvious differences between proteins and peptides, the mechanism of interaction, where an extended peptide is bound to the grove of an enzyme, is remarkably similar. Figure 4A shows a crystal structure a 20-amino acid peptide derived from the heat stable protein kinase inhibitor (PKIα) bound to the catalytic subunit of cyclic AMP-dependent protein kinase (cAPK) (PDB ID: 2CPK). In its bound from, the PKIα peptide is characterized by a highly extended conformation. Although this extended bound form is stabilized by a well-developed network of 36 H-bonds, only two of these bonds are intramolecular, with 16 H-bonds being formed with cAPK and remaining 18 H-bonds being formed with water. A very similar situation is observed for complexes between the protein Ser/Thr phosphatase-1 and a 23 amino acid cell-permeable peptide (PDB ID: 4G9J, Figure 4B), or the polypeptide N-acetylgalactosaminyltransferase 2 and the 13 amino acid peptide EA2 (PDB ID: 2FFU, Figure 4C), or human mitochondrial NAD-dependent deacetylase sirtuin-3 and a 12 amino acid peptide derived from the mitochondrial acetyl-coenzyme A synthetase 2-like (PDB ID: 3GLT, Figure 4D), or the protein arginine N-methyltransferase 1 and a 19 amino acid substrate peptide (PDB ID: 1OR8, Figure 4E).

Furthermore, systematic bioinformatics analyses of the peculiarities of the IDP/IDPR-located display sites targeted for PTMs and their adjacent regions showed that their sequence attributes (such as sequence complexity, charge, hydrophobicity, amino acid compositions, etc.) are very similar to those of IDPRs. For the first time, this observation was made for protein phosphorylation and later similar trends were found for sites targeted for methylation, ubiquitination, S-palmitoylation, as well as in protein regions that undergo multiple homologous or heterologous PTM events. This last observation is especially interesting, since it clearly indicates the importance of intrinsic disorder for the PTM-based regulation of proteins that occur not only through the individual effect of a given PTM at a single residue, but also through combined effects over multiple sites undergoing the same or different PTMs. These proteins affected by more than one PTM are commonly involved in transcriptional, posttranscriptional, and developmental processes contain multi-PTM or shared-PTM display sites that are characterized by preferences toward IDPRs exceeding those of the single-PTM sites. Furthermore, it was indicated that MoRFs possess significant preferences for PTM sites, particularly shared PTM sites, suggesting that PTMs play crucial roles in the modulation of this specific type of macromolecular recognition.

Also, the facts that >50% of all proteins are glycosylated, but only ∼5% of all PDB entries have attached glycan chains indicate that glycosylated proteins are often disordered. In agreement with this hypothesis, an analysis of the complete proteomes of eight typical monocotyledonous and dicotyledonous plant species revealed that phosphorylation, acetylation, and O-glycosylation sites were preferentially located within the IDPRs of plant proteins. Similarly, a computational analysis of 20 algae proteomes revealed that phosphorylation, O-glycosylation, and ubiquitination sites, as well as PEST motifs [i.e., regions rich in proline, glutamic acid, serine, and threonine that serve as a signal for protein degradation] preferentially occurred in IDPRs.

Concluding, all these findings strongly suggest that many protein PTM sites are very commonly positioned within the IDPRs. Likely, this is because of the need of the corresponding modifying enzymes to work with a multitude of target sites in a wide variety of rather different protein targets (e.g., to utilize the ‘one-lock-many-keys’ mechanism). Disorder in flanking regions of such PTM sites provides a mean for a single modifying enzyme to bind and modify a wide variety of protein targets via a ‘flexible-lock-pick’ approach.

Structural and Functional Consequences of PTMs in IDPs/IDPRs

Because PTMs are associated with the addition of various chemical groups to target protein, they clearly represent one of the means of altering of the energy landscape of a protein, thereby leading to conformational changes. Curiously, there is no uniform response of a protein structure to PTMs. It was pointed out that the outputs of PTMs are very diverse, ranging from local stabilization or destabilization of transient secondary structure to global disorder-to-order transitions. PTMs can also drive global changes in the protein phase states, for example, driving transitions between intrinsically disordered and ordered states of a protein molecule or between the dispersed monomeric and phase-separated states.

Based on the analysis of the effects of phosphorylation on structural properties of 17 proteins with available structural information for their phosphorylated and non-phosphorylated forms it has been concluded that the types and extent of structural changes could be highly diverse, ranging from local to long-range structural changes, leading to both association and disassociation of protein complexes, and causing both order-to-disorder and disorder-to-order transitions. Extension of this analysis to all proteins for which structures corresponding to their modified and unmodified forms are known revealed that PTMs typically induce small but statistically significant conformational changes at both local and global levels. A few illustrative examples of how PTMs might affect structure and functionality of individual IDPs/IDPRs are given below.

A systematic structural analysis revealed that different PTMs (phosphorylation and acetylation) have a profound effect on the conformational preferences of the intrinsically disordered negative regulatory domain (NRD) of the p53 tumor suppressor, thereby regulating activity of this important protein. Phosphorylation induces structural changes in the p65 subunit of NF-κ B, allowing subsequent p65 ubiquitination and interaction with transcriptional cofactors. Phosphorylation of the ETS domain transcription factor Elk-1 by extracellular signal-regulated kinase (ERK) modulates the interaction of Elk-1 with Mediator and histone acetyltransferases. Phosphorylation of the Drosophila transcription factor Hox at multiple sites regulates interactions of this protein with DNA and other proteins, and plays a role in transcription activation. Comparison of the solution structures of the phosphorylated and non-phosphorylated forms of the E7 protein from HPV-16 revealed that phosphorylation has significant local effect, changing structural and dynamic properties of the 26–29 region located in the close proximity to the retinoblastoma tumor suppressor (pRb) binding LXCXE motif (residues 22–26), thereby affecting the interactability of this protein. Phosphorylation of a member of the group-3 LEA protein family, PM18 protein, did not affect global intrinsically disordered status of this protein, but had profound effects on the salt-tolerance-related functions of this soybean protein. Combined experimental and computational analysis of the effect of phosphorylation on the conformational preferences of the synaptotagmin 1 IDPR revealed that phosphorylation of Thr112 resulted in the disruption of a local disorder-to-order transition likely due to the induction of salt bridges unsuitable for helix formation.

Progressive acetylation has a cumulative effect on the intrinsically disordered tail of the H4 core histone, leading to the decrease in its conformational heterogeneity, combined with the increase in helical propensity and hydrogen bond occupancies, as well as with the formation of spatially clustered lysines that could serve as recognition patches for interaction with proteins engaged in chromatin regulation. The aforementioned cumulative effects of acetylation were shown to be associated with the reduction in the protein net charge and the increase in hydrophobicity caused by the addition of the acetyl groups. Multiple combinatorial PTMs of the C-terminal domain of RNA Polymerase II was shown to coordinate transcription with mRNA processing as well as regulate multiple stages of transcription initiation. Activity of dehydrin/response ABA protein is likely to be regulated by multiple PTMs, such as acetylation, amidation, glycosylation, methylation, myristoylation, nitrosylation, O-linked β-N-acetylglucosamination, palmitoylation, phosphorylation, sumoylation, sulfation, and ubiquitination. It was pointed out that human proteins with multiple PTM sites (Mtp-proteins) contain more IDPRs than proteins carrying no known PTM sites. These Mtp-proteins were shown to be significantly enriched in protein complexes, have more protein partners, and prefer to act as hubs/superhubs in protein–protein interaction (PPI) networks than the proteins carrying no known PTM sites.

Intrinsic Disorder, PTMs, and Human Diseases

Various PTMs can control, modulate, and regulated functions of IDPs and IDPRs. Therefore, human diseases can be caused by aberrant PTMs. In agreement with this hypothesis, all major PTMs, such as acetylation, glycosylation, methylation, palmitoylation, phosphorylation, proteolytic degradation, and ubiquitination, can be altered in various human maladies, including cancer, cardiovascular diseases, diabetes, and neurodegenerative diseases. Systematic computational analysis revealed that ∼5% of the disease-associated mutations in human proteins may affect known PTM sites, with most of the 15 PTM types being found to be disrupted at levels higher than expected by chance. Furthermore, the aforementioned Mtp-proteins were shown to be more prone to be involved in various human diseases than proteins carrying no known PTM sites.

Many malignancies [e.g., colorectal cancer (CRC)] are characterized by the abnormal glycosylation, which is commonly associated with the oncogenesis and cancer progression. Many biomarkers used for diagnosis, prediction, and prognosis of various cancers are characterized by the aberrant N-linked glycosylation. It was also shown that both gain and loss of phosphorylation target sites caused by the somatic mutations may play an active role in cancer pathogenesis. The distortion in the tightly controlled multiple modifications of the important nuclear IDPs, histones, is commonly found in malignancies. For example, CRC is characterized by the abnormal acetylation and methylation of specific histone residues, indicating the usefulness of the histone modification analysis for the diagnosis and prognosis in the CRC patients. Alterations of the PTMs of lysine residues (such as methylation, acetylation, sumoylation, and ubiquitination) of proteins involved in DNA repair are frequently associated with genomic instability, which is the major cause of different diseases, especially cancers. Normal and pathological activities of one of the high-mobility group transcription factors, the Sry-containing protein Sox2, are controlled by normal and pathological phosphorylation, acetylation, ubiquitination, methylation, and SUMOylation. Levels of a master transcriptional repressor REST/NRSF protein (RE-1 silencing transcription factor or neuron-restrictive silencer factor) that can serve as a tumor suppressor or oncogene are controlled by ubiquitination-deubiquitination cycles, with the abnormal upregulation of this protein being detected in glioblastoma, medulloblastoma, and neuroblastoma. Ectodomain shedding of syndecans, which is the proteolytic processing of cell-surface proteoglycans (PGs), is associated with the facilitation of cancer development. It also promotes cancer cell motility and invasion, thereby stimulating aggressiveness of various tumors.

In neurodegeneration, Huntington’s disease (HD) is characterized by aberrant acetylation, methylation, phosphorylation, polyamination, and ubiquitination of histones. Furthermore, significant alterations in acetylation, palmitoylation, phosphorylation, proteolytic cleavage, sumoylation, and ubiquitination are reported for the HD causative protein, Huntingtin (Htt). In Alzheimer’s disease (AD), levels and aggregation of the causative amyloid-β (Aβ) are affected by aberrant proteolytic cleavage of the amyloid precursor protein (APP). Pathogenesis of AD and other tauopathies is associated with altered sumoylation, abnormal hyperphosphorylation, and abnormal truncations of the microtubule-associated protein tau. The pathogenesis of frontotemporal lobar degeneration (FTLD) is associated with the aberrant phosphorylation of a RNA/DNA binding protein TDP-43 (TAR DNA binding protein 43). In the transmissible spongiform encephalopathy (TSE) and other prion diseases, the infectious properties of the prion protein can be altered by changes in the glycosylation status of this protein.

Acquired cardiac disorders, such as arrhythmias and heart failure, are associated with the aberrant functions of the voltage-gated sodium channel isoform 1.5 (NaV1.5) caused by its altered PTMs. The myofilament dysfunction in dilated cardiomyopathy (DCM) is associated with the aberrant phosphorylation of troponins I and T and myosin light chain, as well as with altered oxidation and glycation of sarcomeric proteins. Deregulated phosphorylation and glutathionylation of nitric oxide synthases NOS1 and NOS3 represent an important contributing factor in the pathogenesis of cardiac hypertrophy and failure, myocardial infarction, myocardial ischemia, reperfusion injury, and vascular disease.

In diabetes and hyperhomocysteinemia, the aberrant glycation of fibrinogen is associated with the increased atherothrombotic risk. Also, prolonged increase in the O-GlcNAcylation and sustained increase in the O-GlcNAc (O-linked N-acetylglucosamine) levels are associated with the insulin resistance and glucose toxicity. This is due to the distortions in the complex interplay between phosphorylation and O-GlcNAcylation, since the rise in the GlcNAcylation levels can efficiently modulate the phosphate stoichiometry at most of the sites undergoing phosphorylation-dephosphorylation. Curiously, 381 proteins affected by these diabetes-distorted dual modifications (phosphorylation and O-GlcNAcylation) were shown to have a multitude of biological functions, acting as metabolic enzymes, cytoskeleton regulatory proteins, chaperones, kinases, RNA processing proteins, or transcription factors.

Concluding Remarks

Intrinsic disorder represents a common property found in proteins engaged in recognition, regulation, and control of various signaling events and pathways. Interactions with biological binding partners cause partial or complete folding of many IDPs/IDPRs. Due to the multiple binding specificities and mechanisms, these proteins can be involved in one-to-many and many-to-one interactions. Normally, functions and abundance of IDPs/IDPRs are tightly controlled and modulated by various means, including a wide spectrum of PTMs. Alteration of the mechanisms controlling IDP/IDPR functionality, localization, and cellular levels can be detrimental, causing various maladies. Often, protein-based pathogenicity originates from aberrant PTMs and altered degradation of IDPs/IDPRs. It seems that PTMs represent very important cellular mechanisms that affect the abundance, cellular distribution, foldability, or functionality of IDPs/IDPRs, with altered PTMs being commonly associated with pathological transformations of these important cellular players.

Author Contributions

VU conceived the idea. VU and AD collected and analyzed the literature data, and wrote and edited the manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 192

  1. 1.

    Abraham G. N. Podell D. N. (1981 ). Pyroglutamic acid. Non-metabolic formation, function in proteins and peptides, and characteristics of the enzymes effecting its removal. Mol. Cell. Biochem. 38 181–190.

    Not in our library10.1007/bf00235695

  2. 2.

    Antz C. Geyer M. Fakler B. Schott M. K. Guy H. R. Frank R. (1997 ). NMR structure of inactivation gates from mammalian voltage-dependent potassium channels. Nature 385 272–275.

    Not in our library10.1038/385272a0

  3. 3.

    Apweiler R. Hermjakob H. Sharon N. (1999 ). On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim. Biophys. Acta 1473 4–8.

    Not in our library10.1016/s0304-4165(99)00165-8

  4. 4.

    Ardito F. Giuliani M. Perrone D. Troiano G. Lo Muzio L. (2017 ). The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review). Int. J. Mol. Med. 40 271–280.

    Not in our library10.3892/ijmm.2017.3036

  5. 5.

    Armstrong C. M. Bezanilla F. (1977 ). Inactivation of the sodium channel. II. Gating current experiments. J. Gen. Physiol. 70 567–590.

    Not in our library10.1085/jgp.70.5.567

  6. 6.

    Arya G. Schlick T. (2009 ). A tale of tails: how histone tails mediate chromatin compaction in different salt and linker histone environments. J. Phys. Chem. A 113 4045–4059.

    Not in our library10.1021/jp810375d

  7. 7.

    Bah A. Forman-Kay J. D. (2016 ). Modulation of intrinsically disordered protein function by post-translational modifications. J. Biol. Chem. 291 6696–6705.

    Not in our library10.1074/jbc.r115.695056

  8. 8.

    Baumann M. Meri S. (2004 ). Techniques for studying protein heterogeneity and post-translational modifications. Expert Rev. Proteomics 1 207–217.

    Not in our library10.1586/14789450.1.2.207

  9. 9.

    Beadle G. W. Ephrussi B. (1936 ). The differentiation of eye pigments in Drosophila as studied by transplantation. Genetics 21 225–247.

    Not in our library10.1093/genetics/21.3.225

  10. 10.

    Beadle G. W. Tatum E. L. (1941 ). Genetic control of biochemical reactions in Neurospora. Proc. Natl. Acad. Sci. U.S.A. 27 499–506.

    Not in our library10.1073/pnas.27.11.499

  11. 11.

    Ben-Dor S. Esterman N. Rubin E. Sharon N. (2004 ). Biases and complex patterns in the residues flanking protein N-glycosylation sites. Glycobiology 14 95–101.

    Not in our library10.1093/glycob/cwh004

  12. 12.

    Bondos S. E. Tan X. X. Matthews K. S. (2006 ). Physical and genetic interactions link hox function with diverse transcription factors and cell signaling proteins. Mol. Cell. Proteomics 5 824–834.

    Not in our library10.1074/mcp.m500256-mcp200

  13. 13.

    Bossemeyer D. Engh R. A. Kinzel V. Ponstingl H. Huber R. (1993 ). Phosphotransferase and substrate binding mechanism of the cAMP-dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 A structure of the complex with Mn2+ adenylyl imidodiphosphate and inhibitor peptide PKI(5-24). EMBO J. 12 849–859.

    Not in our library10.1002/j.1460-2075.1993.tb05725.x

  14. 14.

    Brown C. J. Takayama S. Campen A. M. Vise P. Marshall T. W. Oldfield C. J. (2002 ). Evolutionary rate heterogeneity in proteins with long disordered regions. J. Mol. Evol. 55 104–110.

    Not in our library10.1007/s00239-001-2309-6

  15. 15.

    Brown H. G. Hoh J. H. (1997 ). Entropic exclusion by neurofilament sidearms: a mechanism for maintaining interfilament spacing. Biochemistry 36 15035–15040.

    Not in our library10.1021/bi9721748

  16. 16.

    Buratti E. Baralle F. E. (2008 ). Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front. Biosci. 13 867–878.

    Not in our library10.2741/2727

  17. 17.

    Campbell M. J. Turner B. M. (2013 ). Altered histone modifications in cancer. Adv. Exp. Med. Biol. 754 81–107.

    Not in our library10.1007/978-1-4419-9967-2_4

  18. 18.

    Cancellotti E. Mahal S. P. Somerville R. Diack A. Brown D. Piccardo P. (2013 ). Post-translational changes to PrP alter transmissible spongiform encephalopathy strain properties. EMBO J. 32 756–769.

    Not in our library10.1038/emboj.2013.6

  19. 19.

    Carnicer R. Crabtree M. J. Sivakumaran V. Casadei B. Kass D. A. (2013 ). Nitric oxide synthases in heart failure. Antioxid. Redox Signal. 18 1078–1099.

    Not in our library10.1089/ars.2012.4824

  20. 20.

    Chatterjee J. Beullens M. Sukackaite R. Qian J. Lesage B. Hart D. J. (2012 ). Development of a peptide that selectively activates protein phosphatase-1 in living cells. Angew. Chem. Int. Ed. Engl. 51 10054–10059.

    Not in our library10.1002/anie.201204308

  21. 21.

    Chatterjee S. Senapati P. Kundu T. K. (2012 ). Post-translational modifications of lysine in DNA-damage repair. Essays Biochem. 52 93–111.

    Not in our library10.1042/bse0520093

  22. 22.

    Cheng Y. Oldfield C. J. Meng J. Romero P. Uversky V. N. Dunker A. K. (2007 ). Mining alpha-helix-forming molecular recognition features with cross species sequence alignments. Biochemistry 46 13468–13477.

    Not in our library10.1021/bi7012273

  23. 23.

    Cortese M. S. Uversky V. N. Dunker A. K. (2008 ). Intrinsic disorder in scaffold proteins: getting more from less. Prog. Biophys. Mol. Biol. 98 85–106.

    Not in our library10.1016/j.pbiomolbio.2008.05.007

  24. 24.

    Daily K. M. Radivojac P. Dunker A. K. (2005 ). “Intrinsic disorder and protein modifications: building an SVM predictor for methylation,” in Proceeding of the IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB), San Diego, CA, 475–481.

    Not in our library

  25. 25.

    DeForte S. Uversky V. N. (2016 ). Resolving the ambiguity: making sense of intrinsic disorder when PDB structures disagree. Protein Sci. 25 676–688.

    Not in our library10.1002/pro.2864

  26. 26.

    Deribe Y. L. Pawson T. Dikic I. (2010 ). Post-translational modifications in signal integration. Nat. Struct. Mol. Biol. 17 666–672.

    Not in our library10.1038/nsmb.1842

  27. 27.

    Drake R. R. Schwegler E. E. Malik G. Diaz J. Block T. Mehta A. (2006 ). Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol. Cell. Proteomics 5 1957–1967.

    Not in our library10.1074/mcp.m600176-mcp200

  28. 28.

    Dunker A. K. Brown C. J. Lawson J. D. Iakoucheva L. M. Obradovic Z. (2002a ). Intrinsic disorder and protein function. Biochemistry 41 6573–6582.

    Not in our library10.1021/bi012159+

  29. 29.

    Dunker A. K. Brown C. J. Obradovic Z. (2002b ). Identification and functions of usefully disordered proteins. Adv. Protein Chem. 62 25–49.

    Not in our library10.1016/s0065-3233(02)62004-2

  30. 30.

    Dunker A. K. Cortese M. S. Romero P. Iakoucheva L. M. Uversky V. N. (2005 ). Flexible nets: the roles of intrinsic disorder in protein interaction networks. FEBS J. 272 5129–5148.

    Not in our library10.1111/j.1742-4658.2005.04948.x

  31. 31.

    Dunker A. K. Garner E. Guilliot S. Romero P. Albrecht K. Hart J. (1998 ). Protein disorder and the evolution of molecular recognition: theory, predictions and observations. Pac. Symp. Biocomput. 473–484.

    Not in our library

  32. 32.

    Dunker A. K. Lawson J. D. Brown C. J. Williams R. M. Romero P. Oh J. S. (2001 ). Intrinsically disordered protein. J. Mol. Graph. Model. 19 26–59.

    Not in our library10.1016/s1093-3263(00)00138-8

  33. 33.

    Dunker A. K. Obradovic Z. (2001 ). The protein trinity–linking function and disorder. Nat. Biotechnol. 19 805–806.

    Not in our library10.1038/nbt0901-805

  34. 34.

    Dunker A. K. Obradovic Z. Romero P. Garner E. C. Brown C. J. (2000 ). Intrinsic protein disorder in complete genomes. Genome Inform. Ser. Workshop Genome Inform. 11 161–171.

    Not in our library

  35. 35.

    Dunker A. K. Obradovic Z. Romero P. Kissinger C. Villafranca E. (1997 ). On the importance of being disordered. PDB Newsl. 81 3–5.

    Not in our library

  36. 36.
  37. 37.

    Dunker A. K. Silman I. Uversky V. N. Sussman J. L. (2008b ). Function and structure of inherently disordered proteins. Curr. Opin. Struct. Biol. 18 756–764.

    Not in our library10.1016/j.sbi.2008.10.002

  38. 38.

    Dunker A. K. Uversky V. N. (2008 ). Signal transduction via unstructured protein conduits. Nat. Chem. Biol. 4 229–230.

    Not in our library10.1038/nchembio0408-229

  39. 39.

    Dyson H. J. Wright P. E. (2002 ). Coupling of folding and binding for unstructured proteins. Curr. Opin. Struct. Biol. 12 54–60.

    Not in our library10.1016/s0959-440x(02)00289-0

  40. 40.

    Dyson H. J. Wright P. E. (2005 ). Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol. 6 197–208.

    Not in our library10.1038/nrm1589

  41. 41.

    Ehrnhoefer D. E. Sutton L. Hayden M. R. (2011 ). Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease. Neuroscientist 17 475–492.

    Not in our library10.1177/1073858410390378

  42. 42.

    Ellis R. J. (2001 ). Macromolecular crowding: obvious but underappreciated. Trends Biochem. Sci. 26 597–604.

    Not in our library10.1016/s0968-0004(01)01938-7

  43. 43.

    Ellis R. J. Minton A. P. (2003 ). Cell biology: join the crowd. Nature 425 27–28.

    Not in our library10.1038/425027a

  44. 44.

    ENCODE Project Consortium (2012 ). An integrated encyclopedia of DNA elements in the human genome. Nature 489 57–74.

    Not in our library10.1038/nature11247

  45. 45.

    Farrah T. Deutsch E. W. Hoopmann M. R. Hallows J. L. Sun Z. Huang C. Y. (2013 ). The state of the human proteome in 2012 as viewed through PeptideAtlas. J. Proteome Res. 12 162–171.

    Not in our library10.1021/pr301012j

  46. 46.

    Farrah T. Deutsch E. W. Omenn G. S. Sun Z. Watts J. D. Yamamoto T. (2014 ). State of the human proteome in 2013 as viewed through PeptideAtlas: comparing the kidney, urine, and plasma proteomes for the biology- and disease-driven human proteome project. J. Proteome Res. 13 60–75.

    Not in our library10.1021/pr4010037

  47. 47.

    Fealey M. E. Binder B. P. Uversky V. N. Hinderliter A. Thomas D. D. (2018 ). Structural impact of phosphorylation and dielectric constant variation on synaptotagmin’s IDR. Biophys. J. 114 550–561.

    Not in our library10.1016/j.bpj.2017.12.013

  48. 48.

    Feng Z. P. Keizer D. W. Stevenson R. A. Yao S. Babon J. J. Murphy V. J. (2005 ). Structure and inter-domain interactions of domain II from the blood-stage malarial protein, apical membrane antigen 1. J. Mol. Biol. 350 641–656.

    Not in our library10.1016/j.jmb.2005.05.011

  49. 49.

    Fink A. L. (1995 ). Compact intermediate states in protein folding. Annu. Rev. Biophys. Biomol. Struct. 24 495–522.

    Not in our library10.1146/annurev.bb.24.060195.002431

  50. 50.

    Fisher C. K. Stultz C. M. (2011 ). Constructing ensembles for intrinsically disordered proteins. Curr. Opin. Struct. Biol. 21 426–431.

    Not in our library10.1016/j.sbi.2011.04.001

  51. 51.

    Fulton A. B. (1982 ). How crowded is the cytoplasm? Cell 30 345–347.

    Not in our library10.1016/0092-8674(82)90231-8

  52. 52.

    Galbraith M. D. Saxton J. Li L. Shelton S. J. Zhang H. Espinosa J. M. (2013 ). ERK phosphorylation of MED14 in promoter complexes during mitogen-induced gene activation by Elk-1. Nucleic Acids Res. 41 10241–10253.

    Not in our library10.1093/nar/gkt837

  53. 53.

    Gargalionis A. N. Piperi C. Adamopoulos C. Papavassiliou A. G. (2012 ). Histone modifications as a pathogenic mechanism of colorectal tumorigenesis. Int. J. Biochem. Cell Biol. 44 1276–1289.

    Not in our library10.1016/j.biocel.2012.05.002

  54. 54.

    Gezer U. Holdenrieder S. (2014 ). Post-translational histone modifications in circulating nucleosomes as new biomarkers in colorectal cancer. In Vivo 28 287–292.

    Not in our library

  55. 55.

    Hammer M. R. John P. N. Flynn M. D. Bellingham A. J. Leslie R. D. (1989 ). Glycated fibrinogen: a new index of short-term diabetic control. Ann. Clin. Biochem. 26(Pt 1), 58–62.

    Not in our library10.1177/000456328902600108

  56. 56.
  57. 57.

    Henschen-Edman A. H. (2001 ). Fibrinogen non-inherited heterogeneity and its relationship to function in health and disease. Ann. N. Y. Acad. Sci. 936 580–593.

    Not in our library10.1111/j.1749-6632.2001.tb03546.x

  58. 58.

    Hernandez F. Avila J. (2007 ). Tauopathies. Cell. Mol. Life Sci. 64 2219–2233.

    Not in our library10.1007/s00018-007-7220-x

  59. 59.

    Herren A. W. Bers D. M. Grandi E. (2013 ). Post-translational modifications of the cardiac Na channel: contribution of CaMKII-dependent phosphorylation to acquired arrhythmias. Am. J. Physiol. Heart Circ. Physiol. 305 H431–H445.

    Not in our library10.1152/ajpheart.00306.2013

  60. 60.

    Hoffman M. (2008 ). Alterations of fibrinogen structure in human disease. Cardiovasc. Hematol. Agents Med. Chem. 6 206–211.

    Not in our library10.2174/187152508784871981

  61. 61.

    Holub P. Lalakova J. Cerna H. Pasulka J. Sarazova M. Hrazdilova K. (2012 ). Air2p is critical for the assembly and RNA-binding of the TRAMP complex and the KOW domain of Mtr4p is crucial for exosome activation. Nucleic Acids Res. 40 5679–5693.

    Not in our library10.1093/nar/gks223

  62. 62.

    Horowitz N. H. (1995 ). One-gene-one-enzyme: remembering biochemical genetics. Protein Sci. 4 1017–1019.

    Not in our library10.1002/pro.5560040524

  63. 63.

    Horowitz N. H. Bonner D. Mitchell H. K. Tatum E. L. Beadle G. W. (1945 ). Genic control of biochemical reactions in Neurospora. Am. Nat. 79 304–317. 1993180

    Not in our library10.1086/281267

  64. 64.

    Hoshi T. Zagotta W. N. Aldrich R. W. (1990 ). Biophysical and molecular mechanisms of Shaker potassium channel inactivation. Science 250 533–538.

    Not in our library10.1126/science.2122519

  65. 65.

    Hsu W. L. Oldfield C. Meng J. Huang F. Xue B. Uversky V. N. (2012 ). Intrinsic protein disorder and protein-protein interactions. Pac. Symp. Biocomput. 116–127.

    Not in our library

  66. 66.

    Hsu W. L. Oldfield C. J. Xue B. Meng J. Huang F. Romero P. (2013 ). Exploring the binding diversity of intrinsically disordered proteins involved in one-to-many binding. Protein Sci. 22 258–273.

    Not in our library10.1002/pro.2207

  67. 67.

    Huang Q. Chang J. Cheung M. K. Nong W. Li L. Lee M. T. (2014 ). Human proteins with target sites of multiple post-translational modification types are more prone to be involved in disease. J. Proteome Res. 13 2735–2748.

    Not in our library10.1021/pr401019d

  68. 68.

    Huang Z. Bao S. (2012 ). Ubiquitination and deubiquitination of REST and its roles in cancers. FEBS Lett. 586 1602–1605.

    Not in our library10.1016/j.febslet.2012.04.052

  69. 69.

    Hubbard S. R. (1997 ). Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16 5572–5581.

    Not in our library10.1093/emboj/16.18.5572

  70. 70.

    Iakoucheva L. M. Brown C. J. Lawson J. D. Obradovic Z. Dunker A. K. (2002 ). Intrinsic disorder in cell-signaling and cancer-associated proteins. J. Mol. Biol. 323 573–584.

    Not in our library10.1016/s0022-2836(02)00969-5

  71. 71.

    Iakoucheva L. M. Radivojac P. Brown C. J. O’connor T. R. Sikes J. G. Obradovic Z. (2004 ). The importance of intrinsic disorder for protein phosphorylation. Nucleic Acids Res. 32 1037–1049.

    Not in our library10.1093/nar/gkh253

  72. 72.
  73. 73.

    Jin L. Wei W. Jiang Y. Peng H. Cai J. Mao C. (2009 ). Crystal structures of human SIRT3 displaying substrate-induced conformational changes. J. Biol. Chem. 284 24394–24405.

    Not in our library10.1074/jbc.m109.014928

  74. 74.

    Johnson L. N. Lewis R. J. (2001 ). Structural basis for control by phosphorylation. Chem. Rev. 101 2209–2242.

    Not in our library10.1021/cr000225s

  75. 75.
  76. 76.

    Kalemba E. M. Litkowiec M. (2015 ). Functional characterization of a dehydrin protein from Fagus sylvatica seeds using experimental and in silico approaches. Plant Physiol. Biochem. 97 246–254.

    Not in our library10.1016/j.plaphy.2015.10.011

  77. 77.

    Khoury G. A. Baliban R. C. Floudas C. A. (2011 ). Proteome-wide post-translational modification statistics: frequency analysis and curation of the swiss-prot database. Sci. Rep. 1:90.

    Not in our library10.1038/srep00090

  78. 78.

    Kim M. S. Pinto S. M. Getnet D. Nirujogi R. S. Manda S. S. Chaerkady R. (2014 ). A draft map of the human proteome. Nature 509 575–581.

    Not in our library10.1038/nature13302

  79. 79.

    Kitahara R. Yokoyama S. Akasaka K. (2005 ). NMR snapshots of a fluctuating protein structure: ubiquitin at 30 bar-3 kbar. J. Mol. Biol. 347 277–285.

    Not in our library10.1016/j.jmb.2005.01.052

  80. 80.

    Knighton D. R. Zheng J. H. Ten Eyck L. F. Ashford V. A. Xuong N. H. Taylor S. S. (1991 ). Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253 407–414.

    Not in our library10.1126/science.1862342

  81. 81.

    Komander D. Clague M. J. Urbe S. (2009 ). Breaking the chains: structure and function of the deubiquitinases. Nat. Rev. Mol. Cell Biol. 10 550–563.

    Not in our library10.1038/nrm2731

  82. 82.

    Kovacech B. Novak M. (2010 ). Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer’s disease. Curr. Alzheimer Res. 7 708–716.

    Not in our library10.2174/156720510793611556

  83. 83.

    Kriwacki R. W. Hengst L. Tennant L. Reed S. I. Wright P. E. (1996 ). Structural studies of p21Waf1/Cip1/Sdi1 in the free and Cdk2-bound state: conformational disorder mediates binding diversity. Proc. Natl. Acad. Sci. U.S.A. 93 11504–11509.

    Not in our library10.1073/pnas.93.21.11504

  84. 84.

    Kurotani A. Sakurai T. (2015 ). In silico analysis of correlations between protein disorder and post-translational modifications in algae. Int. J. Mol. Sci. 16 19812–19835.

    Not in our library10.3390/ijms160819812

  85. 85.

    Kurotani A. Tokmakov A. A. Kuroda Y. Fukami Y. Shinozaki K. Sakurai T. (2014 ). Correlations between predicted protein disorder and post-translational modifications in plants. Bioinformatics 30 1095–1103.

    Not in our library10.1093/bioinformatics/btt762

  86. 86.

    Le Gall T. Romero P. R. Cortese M. S. Uversky V. N. Dunker A. K. (2007 ). Intrinsic disorder in the Protein Data Bank. J. Biomol. Struct. Dyn. 24 325–342.

    Not in our library10.1080/07391102.2007.10507123

  87. 87.

    Lee L. Sakurai M. Matsuzaki S. Arancio O. Fraser P. (2013 ). SUMO and Alzheimer’s disease. Neuromol. Med. 15 720–736.

    Not in our library10.1007/s12017-013-8257-7

  88. 88.

    LeWinter M. M. (2005 ). Functional consequences of sarcomeric protein abnormalities in failing myocardium. Heart Fail. Rev. 10 249–257.

    Not in our library10.1007/s10741-005-5254-4

  89. 89.

    Li S. Iakoucheva L. M. Mooney S. D. Radivojac P. (2010 ). Loss of post-translational modification sites in disease. Pac. Symp. Biocomput. 337–347.

    Not in our library10.1142/9789814295291_0036

  90. 90.

    Liebovitch L. S. Selector L. Y. Kline R. P. (1992 ). Statistical properties predicted by the ball and chain model of channel inactivation. Biophys. J. 63 1579–1585.

    Not in our library10.1016/s0006-3495(92)81732-0

  91. 91.

    Liu K. Lin B. Zhao M. Yang X. Chen M. Gao A. (2013 ). The multiple roles for Sox2 in stem cell maintenance and tumorigenesis. Cell. Signal. 25 1264–1271.

    Not in our library10.1016/j.cellsig.2013.02.013

  92. 92.

    Liu Y. Matthews K. S. Bondos S. E. (2008 ). Multiple intrinsically disordered sequences alter DNA binding by the homeodomain of the Drosophila hox protein ultrabithorax. J. Biol. Chem. 283 20874–20887.

    Not in our library10.1074/jbc.m800375200

  93. 93.

    Liu Y. Matthews K. S. Bondos S. E. (2009 ). Internal regulatory interactions determine DNA binding specificity by a Hox transcription factor. J. Mol. Biol. 390 760–774.

    Not in our library10.1016/j.jmb.2009.05.059

  94. 94.

    Liu Y. Yang M. Cheng H. Sun N. Liu S. Li S. (2017 ). The effect of phosphorylation on the salt-tolerance-related functions of the soybean protein PM18, a member of the group-3 LEA protein family. Biochim. Biophys. Acta 1865 1291–1303.

    Not in our library10.1016/j.bbapap.2017.08.020

  95. 95.

    Lowe E. D. Noble M. E. Skamnaki V. T. Oikonomakos N. G. Owen D. J. Johnson L. N. (1997 ). The crystal structure of a phosphorylase kinase peptide substrate complex: kinase substrate recognition. EMBO J. 16 6646–6658.

    Not in our library10.1093/emboj/16.22.6646

  96. 96.

    Lutteke T. Frank M. von der Lieth C. W. (2004 ). Data mining the protein data bank: automatic detection and assignment of carbohydrate structures. Carbohydr. Res. 339 1015–1020.

    Not in our library10.1016/j.carres.2003.09.038

  97. 97.

    Mann M. Jensen O. N. (2003 ). Proteomic analysis of post-translational modifications. Nat. Biotechnol. 21 255–261.

    Not in our library10.1038/nbt0303-255

  98. 98.

    Markiv A. Rambaruth N. D. Dwek M. V. (2012 ). Beyond the genome and proteome: targeting protein modifications in cancer. Curr. Opin. Pharmacol. 12 408–413.

    Not in our library10.1016/j.coph.2012.04.003

  99. 99.

    Marks F. (1996 ). Protein Phosphorylation. New York, NY: VCH Weinheim

    Not in our library10.1002/9783527615032

  100. 100.

    McDonald I. K. Thornton J. M. (1994 ). Satisfying hydrogen bonding potential in proteins. J. Mol. Biol. 238 777–793.

    Not in our library10.1006/jmbi.1994.1334

  101. 101.

    McDowell C. Chen J. Chen J. (2013 ). Potential conformational heterogeneity of p53 bound to S100B(betabeta). J. Mol. Biol. 425 999–1010.

    Not in our library10.1016/j.jmb.2013.01.001

  102. 102.

    McLarty J. L. Marsh S. A. Chatham J. C. (2013 ). Post-translational protein modification by O-linked N-acetyl-glucosamine: its role in mediating the adverse effects of diabetes on the heart. Life Sci. 92 621–627.

    Not in our library10.1016/j.lfs.2012.08.006

  103. 103.

    Mersfelder E. L. Parthun M. R. (2006 ). The tale beyond the tail: histone core domain modifications and the regulation of chromatin structure. Nucleic Acids Res. 34 2653–2662.

    Not in our library10.1093/nar/gkl338

  104. 104.

    Milanovic M. Kracht M. Schmitz M. L. (2014 ). The cytokine-induced conformational switch of nuclear factor kappaB p65 is mediated by p65 phosphorylation. Biochem. J. 457 401–413.

    Not in our library10.1042/bj20130780

  105. 105.

    Minton A. P. (1997 ). Influence of excluded volume upon macromolecular structure and associations in ‘crowded’ media. Curr. Opin. Biotechnol. 8 65–69.

    Not in our library10.1016/s0958-1669(97)80159-0

  106. 106.

    Minton A. P. (2000 ). Protein folding: thickening the broth. Curr. Biol. 10 R97—-99.

    Not in our library10.1016/s0960-9822(00)00301-8

  107. 107.

    Mohan A. Oldfield C. J. Radivojac P. Vacic V. Cortese M. S. Dunker A. K. (2006 ). Analysis of molecular recognition features (MoRFs). J. Mol. Biol. 362 1043–1059.

    Not in our library10.1016/j.jmb.2006.07.087

  108. 108.

    Moumne L. Betuing S. Caboche J. (2013 ). Multiple aspects of gene dysregulation in Huntington’s disease. Front. Neurol. 4:127

    Not in our library10.3389/fneur.2013.00127

  109. 109.

    Mulvenna J. P. Foley F. M. Craik D. J. (2005 ). Discovery, structural determination, and putative processing of the precursor protein that produces the cyclic trypsin inhibitor sunflower trypsin inhibitor 1. J. Biol. Chem. 280 32245–32253.

    Not in our library10.1074/jbc.m506060200

  110. 110.

    Narayana N. Cox S. Shaltiel S. Taylor S. S. Xuong N. (1997 ). Crystal structure of a polyhistidine-tagged recombinant catalytic subunit of cAMP-dependent protein kinase complexed with the peptide inhibitor PKI(5-24) and adenosine. Biochemistry 36 4438–4448.

    Not in our library10.1021/bi961947+

  111. 111.

    Ngounou Wetie A. G. Woods A. G. Darie C. C. (2014 ). Mass spectrometric analysis of post-translational modifications (PTMs) and protein-protein interactions (PPIs). Adv. Exp. Med. Biol. 806 205–235.

    Not in our library10.1007/978-3-319-06068-2_9

  112. 112.

    Niklas K. J. Bondos S. E. Dunker A. K. Newman S. A. (2015 ). Rethinking gene regulatory networks in light of alternative splicing, intrinsically disordered protein domains, and post-translational modifications. Front. Cell Dev. Biol. 3:8.

    Not in our library10.3389/fcell.2015.00008

  113. 113.

    Nogueira M. O. Hosek T. Calcada E. O. Castiglia F. Massimi P. Banks L. (2017 ). Monitoring HPV-16 E7 phosphorylation events. Virology 503 70–75.

    Not in our library10.1016/j.virol.2016.12.030

  114. 114.

    Oldfield C. J. Cheng Y. Cortese M. S. Romero P. Uversky V. N. Dunker A. K. (2005 ). Coupled folding and binding with alpha-helix-forming molecular recognition elements. Biochemistry 44 12454–12470.

    Not in our library10.1021/bi050736e

  115. 115.
  116. 116.

    Park J. J. Lee M. (2013 ). Increasing the alpha 2, 6 sialylation of glycoproteins may contribute to metastatic spread and therapeutic resistance in colorectal cancer. Gut Liver 7 629–641.

    Not in our library10.5009/gnl.2013.7.6.629

  117. 117.

    Pejaver V. Hsu W. L. Xin F. Dunker A. K. Uversky V. N. Radivojac P. (2014 ). The structural and functional signatures of proteins that undergo multiple events of post-translational modification. Protein Sci. 23 1077–1093.

    Not in our library10.1002/pro.2494

  118. 118.

    Peng Z. Mizianty M. J. Xue B. Kurgan L. Uversky V. N. (2012 ). More than just tails: intrinsic disorder in histone proteins. Mol. Biosyst. 8 1886–1901.

    Not in our library10.1039/c2mb25102g

  119. 119.

    Peng Z. Yan J. Fan X. Mizianty M. J. Xue B. Wang K. (2014 ). Exceptionally abundant exceptions: comprehensive characterization of intrinsic disorder in all domains of life. Cell. Mol. Life Sci. 72 137–151.

    Not in our library10.1007/s00018-014-1661-9

  120. 120.

    Plaxco K. W. Gross M. (1997 ). Cell biology. The importance of being unfolded. Nature 386 657–659.

    Not in our library10.1038/386657a0

  121. 121.

    Pontius B. W. (1993 ). Close encounters: why unstructured, polymeric domains can increase rates of specific macromolecular association. Trends Biochem. Sci. 18 181–186.

    Not in our library10.1016/0968-0004(93)90111-y

  122. 122.

    Ptitsyn O. B. (1995 ). Molten globule and protein folding. Adv. Protein Chem. 47 83–229.

    Not in our library10.1016/s0065-3233(08)60546-x

  123. 123.

    Ptitsyn O. B. Bychkova V. E. Uversky V. N. (1995 ). Kinetic and equilibrium folding intermediates. Philos. Trans. R. Soc. Lond. B Biol. Sci. 348 35–41.

    Not in our library10.1098/rstb.1995.0043

  124. 124.

    Radford S. E. (2000 ). Protein folding: progress made and promises ahead. Trends Biochem. Sci. 25 611–618.

    Not in our library10.1016/s0968-0004(00)01707-2

  125. 125.

    Radivojac P. Baenziger P. H. Kann M. G. Mort M. E. Hahn M. W. Mooney S. D. (2008 ). Gain and loss of phosphorylation sites in human cancer. Bioinformatics 24 i241–i247.

    Not in our library10.1093/bioinformatics/btn267

  126. 126.

    Radivojac P. Iakoucheva L. M. Oldfield C. J. Obradovic Z. Uversky V. N. Dunker A. K. (2007 ). Intrinsic disorder and functional proteomics. Biophys. J. 92 1439–1456.

    Not in our library10.1529/biophysj.106.094045

  127. 127.

    Radivojac P. Obradovic Z. Smith D. K. Zhu G. Vucetic S. Brown C. J. (2004 ). Protein flexibility and intrinsic disorder. Protein Sci. 13 71–80.

    Not in our library10.1110/ps.03128904

  128. 128.

    Radivojac P. Vacic V. Haynes C. Cocklin R. R. Mohan A. Heyen J. W. (2010 ). Identification, analysis, and prediction of protein ubiquitination sites. Proteins 78 365–380.

    Not in our library10.1002/prot.22555

  129. 129.

    Rechsteiner M. Rogers S. W. (1996 ). PEST sequences and regulation by proteolysis. Trends Biochem. Sci. 21 267–271.

    Not in our library10.1016/s0968-0004(96)10031-1

  130. 130.

    Reddy K. D. Malipeddi J. Deforte S. Pejaver V. Radivojac P. Uversky V. N. (2017 ). Physicochemical sequence characteristics that influence S-palmitoylation propensity. J. Biomol. Struct. Dyn. 35 2337–2350.

    Not in our library10.1080/07391102.2016.1217275

  131. 131.

    Reddy P. J. Ray S. Srivastava S. (2015 ). The quest of the human proteome and the missing proteins: digging deeper. OMICS 19 276–282.

    Not in our library10.1089/omi.2015.0035

  132. 132.

    Rivas G. Ferrone F. Herzfeld J. (2004 ). Life in a crowded world. EMBO Rep. 5 23–27.

    Not in our library10.1038/sj.embor.7400056

  133. 133.

    Romero P. Obradovic Z. Kissinger C. R. Villafranca J. E. Garner E. Guilliot S. (1998 ). Thousands of proteins likely to have long disordered regions. Pac. Symp. Biocomput. 437–448.

    Not in our library

  134. 134.

    Romero P. Obradovic Z. Li X. Garner E. C. Brown C. J. Dunker A. K. (2001 ). Sequence complexity of disordered protein. Proteins 42 38–49.

    Not in our library10.1002/1097-0134(20010101)42:1<38::aid-prot50>3.0.co;2-3

  135. 135.

    Ross J. L. (2016 ). The dark matter of biology. Biophys. J. 111 909–916.

    Not in our library10.1016/j.bpj.2016.07.037

  136. 136.
  137. 137.

    Schulz G. E. (1979 ). “Nucleotide binding proteins,” in Molecular Mechanism of Biological Recognition, ed. Balaban M. (New York, NY: Elsevier), 79–94.

    Not in our library

  138. 138.

    Shliaha P. V. Baird M. A. Nielsen M. M. Gorshkov V. Bowman A. P. Kaszycki J. L. (2017 ). Characterization of complete histone tail proteoforms using differential ion mobility spectrometry. Anal. Chem. 89 5461–5466.

    Not in our library10.1021/acs.analchem.7b00379

  139. 139.

    Sirota F. L. Maurer-Stroh S. Eisenhaber B. Eisenhaber F. (2015 ). Single-residue posttranslational modification sites at the N-terminus, C-terminus or in-between: to be or not to be exposed for enzyme access. Proteomics 15 2525–2546.

    Not in our library10.1002/pmic.201400633

  140. 140.

    Smith L. M. Kelleher N. L. Consortium for Top Down Proteomics (2013 ). Proteoform: a single term describing protein complexity. Nat. Methods 10 186–187.

    Not in our library10.1038/nmeth.2369

  141. 141.

    Spolar R. S. Record M. T. Jr. (1994 ). Coupling of local folding to site-specific binding of proteins to DNA. Science 263 777–784.

    Not in our library10.1126/science.8303294

  142. 142.

    Tan X. X. Bondos S. Li L. Matthews K. S. (2002 ). Transcription activation by ultrabithorax Ib protein requires a predicted alpha-helical region. Biochemistry 41 2774–2785.

    Not in our library10.1021/bi011967y

  143. 143.

    ter Haar E. Coll J. T. Austen D. A. Hsiao H. M. Swenson L. Jain J. (2001 ). Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat. Struct. Biol. 8 593–596.

    Not in our library10.1038/89624

  144. 144.

    Theocharis A. D. Skandalis S. S. Tzanakakis G. N. Karamanos N. K. (2010 ). Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J. 277 3904–3923.

    Not in our library10.1111/j.1742-4658.2010.07800.x

  145. 145.

    Tian Y. Zhang H. (2013 ). Characterization of disease-associated N-linked glycoproteins. Proteomics 13 504–511.

    Not in our library10.1002/pmic.201200333

  146. 146.

    Tokmakov A. A. Kurotani A. Takagi T. Toyama M. Shirouzu M. Fukami Y. (2012 ). Multiple post-translational modifications affect heterologous protein synthesis. J. Biol. Chem. 287 27106–27116.

    Not in our library10.1074/jbc.m112.366351

  147. 147.

    Tompa P. (2002 ). Intrinsically unstructured proteins. Trends Biochem. Sci. 27 527–533.

    Not in our library10.1016/s0968-0004(02)02169-2

  148. 148.

    Tompa P. (2005 ). The interplay between structure and function in intrinsically unstructured proteins. FEBS Lett. 579 3346–3354.

    Not in our library10.1016/j.febslet.2005.03.072

  149. 149.

    Tompa P. Csermely P. (2004 ). The role of structural disorder in the function of RNA and protein chaperones. FASEB J. 18 1169–1175.

    Not in our library10.1096/fj.04-1584rev

  150. 150.

    Tompa P. Fuxreiter M. Oldfield C. J. Simon I. Dunker A. K. Uversky V. N. (2009 ). Close encounters of the third kind: disordered domains and the interactions of proteins. Bioessays 31 328–335.

    Not in our library10.1002/bies.200800151

  151. 151.

    Tuccillo F. M. de Laurentiis A. Palmieri C. Fiume G. Bonelli P. Borrelli A. (2014 ). Aberrant glycosylation as biomarker for cancer: focus on CD43. Biomed Res. Int. 2014:742831.

    Not in our library10.1155/2014/742831

  152. 152.

    Turoverov K. K. Kuznetsova I. M. Uversky V. N. (2010 ). The protein kingdom extended: ordered and intrinsically disordered proteins, their folding, supramolecular complex formation, and aggregation. Prog. Biophys. Mol. Biol. 102 73–84.

    Not in our library10.1016/j.pbiomolbio.2010.01.003

  153. 153.

    Uhlen M. Bjorling E. Agaton C. Szigyarto C. A. Amini B. Andersen E. (2005 ). A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell. Proteomics 4 1920–1932.

    Not in our library10.1074/mcp.m500279-mcp200

  154. 154.

    Uversky V. N. (2002a ). Natively unfolded proteins: a point where biology waits for physics. Protein Sci. 11 739–756.

    Not in our library10.1110/ps.4210102

  155. 155.

    Uversky V. N. (2002b ). What does it mean to be natively unfolded? Eur. J. Biochem. 269 2–12.

    Not in our library10.1046/j.0014-2956.2001.02649.x

  156. 156.

    Uversky V. N. (2003 ). Protein folding revisited. A polypeptide chain at the folding-misfolding-nonfolding cross-roads: which way to go? Cell. Mol. Life Sci. 60 1852–1871.

    Not in our library10.1007/s00018-003-3096-6

  157. 157.
  158. 158.

    Uversky V. N. (2013a ). A decade and a half of protein intrinsic disorder: biology still waits for physics. Protein Sci. 22 693–724.

    Not in our library10.1002/pro.2261

  159. 159.

    Uversky V. N. (2013b ). Intrinsic disorder-based protein interactions and their modulators. Curr. Pharm. Des. 19 4191–4213.

    Not in our library10.2174/1381612811319230005

  160. 160.

    Uversky V. N. (2013c ). Unusual biophysics of intrinsically disordered proteins. Biochim. Biophys. Acta 1834 932–951.

    Not in our library10.1016/j.bbapap.2012.12.008

  161. 161.

    Uversky V. N. (2014 ). Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators. Front. Mol. Biosci. 1:6.

    Not in our library10.3389/fmolb.2014.00006

  162. 162.

    Uversky V. N. (2015 ). Functional roles of transiently and intrinsically disordered regions within proteins. FEBS J. 282 1182–1189.

    Not in our library10.1111/febs.13202

  163. 163.

    Uversky V. N. (2016a ). Dancing protein clouds: the strange biology and chaotic physics of intrinsically disordered proteins. J. Biol. Chem. 291 6681–6688.

    Not in our library10.1074/jbc.r115.685859

  164. 164.

    Uversky V. N. (2016b ). (Intrinsically disordered) splice variants in the proteome: implications for novel drug discovery. Genes Genomics 38 577–594.

    Not in our library10.1007/s13258-015-0384-0

  165. 165.
  166. 166.

    Uversky V. N. Dunker A. K. (2010 ). Understanding protein non-folding. Biochim. Biophys. Acta 1804 1231–1264.

    Not in our library10.1016/j.bbapap.2010.01.017

  167. 167.

    Uversky V. N. Dunker A. K. (2013 ). The case for intrinsically disordered proteins playing contributory roles in molecular recognition without a stable 3D structure. F1000 Biol. Rep. 5:1.

    Not in our library10.3410/b5-1

  168. 168.

    Uversky V. N. Gillespie J. R. Fink A. L. (2000 ). Why are “natively unfolded” proteins unstructured under physiologic conditions? Proteins 41 415–427.

    Not in our library10.1002/1097-0134(20001115)41:3<415::aid-prot130>3.0.co;2-7

  169. 169.

    Uversky V. N. Oldfield C. J. Dunker A. K. (2005 ). Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling. J. Mol. Recognit. 18 343–384.

    Not in our library10.1002/jmr.747

  170. 170.

    Uversky V. N. Oldfield C. J. Dunker A. K. (2008 ). Intrinsically disordered proteins in human diseases: introducing the D2 concept. Annu. Rev. Biophys. 37 215–246.

    Not in our library10.1146/annurev.biophys.37.032807.125924

  171. 171.

    Uversky V. N. Ptitsyn O. B. (1994 ). “Partly folded” state, a new equilibrium state of protein molecules: four-state guanidinium chloride-induced unfolding of beta-lactamase at low temperature. Biochemistry 33 2782–2791.

    Not in our library10.1021/bi00176a006

  172. 172.

    Uversky V. N. Ptitsyn O. B. (1996 ). Further evidence on the equilibrium “pre-molten globule state”: four-state guanidinium chloride-induced unfolding of carbonic anhydrase B at low temperature. J. Mol. Biol. 255 215–228.

    Not in our library10.1006/jmbi.1996.0018

  173. 173.

    Vacic V. Oldfield C. J. Mohan A. Radivojac P. Cortese M. S. Uversky V. N. (2007 ). Characterization of molecular recognition features, MoRFs, and their binding partners. J. Proteome Res. 6 2351–2366.

    Not in our library10.1021/pr0701411

  174. 174.

    van den Berg B. Ellis R. J. Dobson C. M. (1999 ). Effects of macromolecular crowding on protein folding and aggregation. EMBO J. 18 6927–6933.

    Not in our library10.1093/emboj/18.24.6927

  175. 175.

    Vucetic S. Xie H. Iakoucheva L. M. Oldfield C. J. Dunker A. K. Obradovic Z. (2007 ). Functional anthology of intrinsic disorder. 2. Cellular components, domains, technical terms, developmental processes, and coding sequence diversities correlated with long disordered regions. J. Proteome Res. 6 1899–1916.

    Not in our library10.1021/pr060393m

  176. 176.

    Walsh C. T. Garneau-Tsodikova S. Gatto G. J. Jr. (2005 ). Protein posttranslational modifications: the chemistry of proteome diversifications. Angew. Chem. Int. Ed. Engl. 44 7342–7372.

    Not in our library10.1002/anie.200501023

  177. 177.

    Wang J. Z. Xia Y. Y. Grundke-Iqbal I. Iqbal K. (2013 ). Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J. Alzheimers Dis. 33(Suppl. 1), S123–S139.

    Not in our library10.3233/jad-2012-129031

  178. 178.

    Wang Z. Gucek M. Hart G. W. (2008 ). Cross-talk between GlcNAcylation and phosphorylation: site-specific phosphorylation dynamics in response to globally elevated O-GlcNAc. Proc. Natl. Acad. Sci. U.S.A. 105 13793–13798.

    Not in our library10.1073/pnas.0806216105

  179. 179.

    Ward J. J. Sodhi J. S. Mcguffin L. J. Buxton B. F. Jones D. T. (2004 ). Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. J. Mol. Biol. 337 635–645.

    Not in our library10.1016/j.jmb.2004.02.002

  180. 180.

    Winogradoff D. Echeverria I. Potoyan D. A. Papoian G. A. (2015 ). The acetylation landscape of the H4 histone tail: disentangling the interplay between the specific and cumulative effects. J. Am. Chem. Soc. 137 6245–6253.

    Not in our library10.1021/jacs.5b00235

  181. 181.

    Witze E. S. Old W. M. Resing K. A. Ahn N. G. (2007 ). Mapping protein post-translational modifications with mass spectrometry. Nat. Methods 4 798–806.

    Not in our library10.1038/nmeth1100

  182. 182.

    Wright P. E. Dyson H. J. (1999 ). Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J. Mol. Biol. 293 321–331.

    Not in our library10.1006/jmbi.1999.3110

  183. 183.

    Xie H. Vucetic S. Iakoucheva L. M. Oldfield C. J. Dunker A. K. Obradovic Z. (2007a ). Functional anthology of intrinsic disorder. 3. Ligands, post-translational modifications, and diseases associated with intrinsically disordered proteins. J. Proteome Res. 6 1917–1932.

    Not in our library10.1021/pr060394e

  184. 184.

    Xie H. Vucetic S. Iakoucheva L. M. Oldfield C. J. Dunker A. K. Uversky V. N. (2007b ). Functional anthology of intrinsic disorder. 1. Biological processes and functions of proteins with long disordered regions. J. Proteome Res. 6 1882–1898.

    Not in our library10.1021/pr060392u

  185. 185.

    Xin F. Radivojac P. (2012 ). Post-translational modifications induce significant yet not extreme changes to protein structure. Bioinformatics 28 2905–2913.

    Not in our library10.1093/bioinformatics/bts541

  186. 186.

    Xue B. Dunker A. K. Uversky V. N. (2012 ). Orderly order in protein intrinsic disorder distribution: disorder in 3500 proteomes from viruses and the three domains of life. J. Biomol. Struct. Dyn. 30 137–149.

    Not in our library10.1080/07391102.2012.675145

  187. 187.

    Yang X. J. (2005 ). Multisite protein modification and intramolecular signaling. Oncogene 24 1653–1662.

    Not in our library10.1038/sj.onc.1208173

  188. 188.

    Yogesha S. D. Mayfield J. E. Zhang Y. (2014 ). Cross-talk of phosphorylation and prolyl isomerization of the C-terminal domain of RNA Polymerase II. Molecules 19 1481–1511.

    Not in our library10.3390/molecules19021481

  189. 189.

    Zhang X. Cheng X. (2003 ). Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides. Structure 11 509–520.

    Not in our library10.1016/s0969-2126(03)00071-6

  190. 190.

    Zimmerman S. B. Minton A. P. (1993 ). Macromolecular crowding: biochemical, biophysical, and physiological consequences. Annu. Rev. Biophys. Biomol. Struct. 22 27–65.

    Not in our library10.1146/annurev.bb.22.060193.000331

  191. 191.

    Zimmerman S. B. Trach S. O. (1991 ). Estimation of macromolecule concentrations and excluded volume effects for the cytoplasm of Escherichia coli. J. Mol. Biol. 222 599–620.

    Not in our library10.1016/0022-2836(91)90499-v

  192. 192.

    Zor T. Mayr B. M. Dyson H. J. Montminy M. R. Wright P. E. (2002 ). Roles of phosphorylation and helix propensity in the binding of the KIX domain of CREB-binding protein by constitutive (c-Myb) and inducible (CREB) activators. J. Biol. Chem. 277 42241–42248.

    Not in our library10.1074/jbc.m207361200

Cited by papers we hold 4

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.